Form 8-K - Current report:
SEC Accession No. 0001641172-25-000742
Filing Date
2025-03-26
Accepted
2025-03-26 16:05:33
Documents
17
Period of Report
2025-03-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 52269
2 ex2-1.htm EX-2.1 29194
3 ex10-1.htm EX-10.1 170386
4 ex99-1.htm EX-99.1 13669
5 ex99-1_001.jpg GRAPHIC 36325
  Complete submission text file 0001641172-25-000742.txt   540479

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE evfm-20250320.xsd EX-101.SCH 3009
7 XBRL LABEL FILE evfm-20250320_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE evfm-20250320_pre.xml EX-101.PRE 24161
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3587
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 25773166
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)